A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants
Condition: Prostatic Neoplasms Interventions: Radiation: Radiotherapy; Drug: LHRHa; Drug: Apalutamide Sponsor: Janssen-Cilag Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials